In this segment, the discussion shifts to the use of biosimilars in the treatment of neovascular age-related macular edema (nAMD) and diabetic macular edema (DME). David Eichenbaum, MD asks the panelists about their thoughts on biosimilar use, particularly with the current commercially available ranibizumab biosimilar. Seenu Hariprasad, MD shares his experience with biosimilars in his practice. He expresses that biosimilars have been helpful in his practice, especially in situations involving step edits and insurance issues. He notes that biosimilars, while cost-effective, belong to an older generation of drugs and are not interchangeable with the newer extended-durability agents. He emphasizes the importance of recognizing the limitations and differences in efficacy and durability. Kenneth Fan, MD, MBA discusses the practical aspects of using biosimilars, mentioning that step mandates often play a role in their utilization. Fan points out that if patients do well on a biosimilar without adverse events and remain dry, he tends to continue with it. However, if there are issues or a need for a more effective treatment, he considers switching to a newer agent. The conversation touches on the role of biosimilars in the context of step edits, patient adherence, and the anticipation of aflibercept biosimilars in the future. The panelists express a range of viewpoints, emphasizing the need to balance cost considerations with ensuring effective and safe treatment for patients.

This summary was AI-generated and edited for clarity.